ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Cardiomyopathies: 2024 Wrap Up

Cardiology 2024 Year in Review

A. Masri

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

PET Imagining in Cardiac Amyloidosis

NYU Langone

S. Dorbala

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF in Women

Scripps Health

B. Borlaug

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

SGLT2 Inhibition in 2024: Use in Heart Failure and Mechanism of Acti…

28th Annual Heart Failure 2024: An Update on Therapy

M. Packer

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Using Cardiac MRI to Assess Progression and Treatment Response

The France Foundation

D. Kwon

Patient Perspective: Cardiac Amyloidosis

Scripps Health

M. Nichols

Cardiotoxicity: Anthracyclines

Scripps Health

M. Davis

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

The Valve Trials Are Done: Interventional HFpEF Is the Next Big Thing

Northwestern Medicine Bluhm Cardiovascular Institute

S. Shah

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin

ACC 2024 Insights: Stop the Meds! Treat the Comorbidities for Optima…

ACC 2024 Insights

K. Williams

Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…

Mary E. Money